Altintas Devrim, Kokcu Arif, Tosun Migraci, Cetinkaya Mehmet B, Kandemir Bedri
Departments of Obstetrics and Gynecology, Samsun, Turkey.
J Obstet Gynaecol Res. 2008 Dec;34(6):1014-9. doi: 10.1111/j.1447-0756.2008.00807.x.
In the present study, we aimed to compare the effects of cetrorelix and leuprolide on endometriosis.
This randomized, placebo-controlled, single-blind, experimental study was performed on 45 Wistar adult female rats in the Experimental Surgery Laboratory at Ondokuz Mayis University. After the peritoneal implantation of endometrial tissue, rats were randomized to three equal intervention groups: (i) control group, (ii) leuprolide group, and (iii) cetrorelix group. Six weeks later, following implant volume measurements (volume-1) by performing a second laparotomy, saline (0.1 cc/rat) was administered subcutaneously to the control group once a week, leuprolide (0.075 mg/kg) subcutaneously to the leuprolide group twice at 4-week intervals and cetrorelix (0.001 mg/rat/day) subcutaneously to the cetrorelix group for 8 weeks. At the end of the treatment, by performing a third laparotomy, implant volumes were remeasured (volume-2) and implants were totally excised for histopathological examination. The volume-1 and volume-2 values within the groups, and stromal and glandular tissue scores between the groups were compared.
In both the leuprolide group and the cetrorelix group, volume-2 as compared to volume-1 had significantly reduced (P < 0.01, P < 0.01 respectively), while there was no significant volume change in the control group (P > 0.05). In this group, when compared with the control group, glandular and stromal tissues had significantly lessened (P < 0.01, P < 0.01 respectively).
Leuprolide and cetrorelix were found to have similar efficacy in the regression of both the size and the histological structure of experimental endometriotic implants.
在本研究中，我们旨在比较西曲瑞克和亮丙瑞林对子宫内膜异位症的影响。
本随机、安慰剂对照、单盲实验研究在奥尔杜大学实验外科实验室对45只成年雌性Wistar大鼠进行。在将子宫内膜组织植入腹膜后，大鼠被随机分为三个相等的干预组：（i）对照组，（ii）亮丙瑞林组，和（iii）西曲瑞克组。六周后，通过第二次剖腹手术测量植入物体积（体积-1），对照组每周皮下注射一次生理盐水（0.1 cc/只大鼠），亮丙瑞林组每4周皮下注射两次亮丙瑞林（0.075 mg/kg），西曲瑞克组皮下注射西曲瑞克（0.001 mg/只大鼠/天），持续8周。治疗结束时，通过第三次剖腹手术重新测量植入物体积（体积-2），并将植入物完全切除进行组织病理学检查。比较组内体积-1和体积-2值以及组间基质和腺体组织评分。
亮丙瑞林组和西曲瑞克组的体积-2与体积-1相比均显著减小（分别为P < 0.01，P < 0.01），而对照组体积无显著变化（P > 0.05）。在该组中，与对照组相比，腺体和基质组织显著减少（分别为P < 0.01，P < 0.01）。
发现亮丙瑞林和西曲瑞克在使实验性子宫内膜异位植入物的大小和组织结构消退方面具有相似的疗效。
